Indian Journal of Medical Research最新文献

{"title":"Trend of immunization & gap in vaccine doses as observed in National Family Health Survey rounds in India.","authors":"Meenu Kalia, Megha Sharma, Ravi Rohilla, Kirtan Rana","doi":"10.25259/ijmr_1770_23","DOIUrl":"10.25259/ijmr_1770_23","url":null,"abstract":"<p><p>Background & objectives Immunization is an efficient and cost-effective way of lowering the infectious disease related morbidity and mortality in the community. The current study reviewed the trend of immunization, gaps in doses of vaccine given at the same time and gaps between the doses of same vaccine from National Family Health Survey (NFHS 1-5) rounds. Methods The current study extracted data from all five NFHS rounds conducted from 1992-93 to 2019-21. The study analyzed the State-wise and demography-wise distribution of trends of immunization from NFHS-1 to NFHS-5. State wise distribution of change in vaccination coverage between NFHS-4 and 5 was analyzed. The study also assessed the State-wise trends of fully vaccinated and unvaccinated children from NFHS 1-5. Results The northeastern States had maximum gap between the vaccination given at birth i.e., 47.3 per cent between BCG and Hepatitis B, and 32.8 per cent between BCG and birth dose of OPV in Manipur in NFHS -5. A gradual rise in the percentage of male (40.2%) and female (41.9%) childrens' vaccination was found across the NFHS rounds with reduction in gap between the male and female vaccination from NFHS-1 (2.6%) to NFHS-5 (0.9%). The percentage of vaccination decreased proportionately with birth order. The vaccination coverage has increased in both urban and rural population, but the rise was higher in rural (45.9%) areas than urban (24.8%). An increase in percentage of fully vaccinated children by 41.2 per cent and decrease in percentage of non-vaccinated children by 26.4 per cent was observed from NFHS-1 to NFHS-5. Interpretation & conclusions Our analysis clearly suggests that immunization coverage has improved over a period of time but the variability in vaccine coverage across States and gap in vaccine doses needs attention of the policy makers to cover this for achieving our national immunization goals.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"303-311"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An update on recombinant vaccines against leishmaniasis.","authors":"Shital Shital, Evanka Madan, Angamuthu Selvapandiyan, Nirmal Kumar Ganguly","doi":"10.25259/IJMR_1040_2024","DOIUrl":"10.25259/IJMR_1040_2024","url":null,"abstract":"<p><p>Leishmaniasis is a parasitic disease caused by various species of the Leishmania parasite, manifesting in visceral (VL), cutaneous (CL), and mucocutaneous (MCL) forms. To combat this debilitating disease, various vaccines candidates including proteins, DNA, vectors, adjuvants, and recombinant whole parasites have been developed and tested experimentally and preclinically against several Leishmania species. Some vaccines have already entered human clinical trials. These vaccines aim to induce protective immunity using specific antigens. This review examines all efforts to develop recombinant vaccines against the parasite, analyzing successes including commercially available canine vaccines and the overall challenges faced in the quest to eradicate the disease. Additionally, recent advances in vaccine delivery systems, such as viral vectors and non-pathogenic bacteria, offer promising avenues to enhance immunogenicity and improve the targeted delivery of antigens, potentially leading to more effective and long-lasting immune responses. By understanding past and current efforts, future strategies can be refined to create more effective vaccines and ultimately control or eradicate this parasitic disease.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"323-337"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of health education on acceptance of human papilloma virus vaccine among parents of adolescent girls of Bishnupur, Manipur: A quasi-experimental study.","authors":"K Dhinu, Sandra Fernandez, Avantika Gupta, Vijaya Elangbam","doi":"10.25259/IJMR_49_2024","DOIUrl":"10.25259/IJMR_49_2024","url":null,"abstract":"<p><p>Background & objectives India contributes maximum to world's cervical cancer burden. Prevention through vaccination is one of the pillars of the global strategy adopted by the World Health Organization (WHO) for the elimination of cervical cancer. Uptake of human papillomavirus (HPV) vaccine, which is about to be introduced in Universal Immunization Programme can be predicted by assessing its acceptance. Methods A quasi-experimental study was conducted among parents of adolescent girls of Bishnupur from February to May 2023 to evaluate the effect of a one-on-one health educational intervention programme on acceptance of the HPV vaccine. Data were collected by face-to-face interviews using a structured questionnaire based on the Health Belief Model from 70 participants selected through convenience sampling. Participants who responded 'definitely yes' to getting their daughters vaccinated with the HPV vaccine were considered as 'vaccine acceptant'. Health education comprised three sessions two wk apart. Descriptive statistics, Cochrane's Q and ANOVA were applied using SPSS 26. Results The median age of the participants was 38 (IQR: 34-44) yr, and 77.1 per cent were females. HPV vaccine acceptance improved significantly over time from 61.4 to 81.4 to 88.6 per cent (P=0.001), respectively. On application of repeated measure ANOVA, perceived benefits of vaccination (P<0.001) and perceived susceptibility to disease (P<0.001) improved significantly across the three time points, whereas perceived severity (P=0.051) and perceived barriers (P=0.367) did not. Interpretation & conclusions Health education intervention was effective at improving vaccine acceptance. Awareness programmes before the rollout of HPV vaccination and continuous re-enforcement would improve parents' perceived benefits and thereby potentially increase vaccine coverage.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"346-353"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TB-vaccines: Current status & challenges.","authors":"Kuldeep Singh Sachdeva, Vineet K Chadha","doi":"10.25259/IJMR_1478_2024","DOIUrl":"10.25259/IJMR_1478_2024","url":null,"abstract":"<p><p>Tuberculosis continues to be among the leading causes of morbidity as well as mortality. It is appreciated that our aim of eliminating TB in the foreseeable future will not be realized until we have a new vaccine with significant efficacy among diverse populations and all age-groups. Although impressive strides have been made in more refined development of new TB vaccines based on learnings from past experiences, the substitute or a booster vaccine for the BCG vaccine is not available yet. This article puts in perspective the recent efforts in re-positioning BCG, development of newer vaccines based on novel approaches, the current TB vaccine pipeline, yet unmet challenges in vaccine development, exploring newer ideas in vaccine development and what the future holds.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"338-345"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethics & utility of controlled human infection studies (CHIS) in low- & middle-income countries.","authors":"Jake Daniel Eberts, Nir Eyal, Sayantan Banerjee","doi":"10.25259/IJMR_985_2024","DOIUrl":"10.25259/IJMR_985_2024","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"262-266"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humanly Possibly.","authors":"Katherine L O'Brien","doi":"10.25259/IJMR_1608_2024","DOIUrl":"10.25259/IJMR_1608_2024","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"312-314"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of leprosy vaccines across the globe: A systematic review & meta-analysis of randomized controlled trials.","authors":"Shreyashi Dasgupta, Shatavisa Mukherjee, Chiranjib Bagchi, Saibal Das, Indranil Saha, Manoj Kalita, Bhavani Shankara Bagepally, Subhasish Kamal Guha","doi":"10.25259/IJMR_1289_2024","DOIUrl":"10.25259/IJMR_1289_2024","url":null,"abstract":"<p><p>Background & objectives Although multi-drug therapy has decreased the burden of disease, leprosy is yet to be eliminated. Accelerating progress requires optimal use of existing tools, advanced diagnostic tests, newer drugs, and vaccines. The search for a vaccine with therapeutic and preventive potential is ongoing, but evidence on effectiveness and safety is lacking. This systematic review and meta-analysis will evaluate and compare the clinical efficacy, immunogenicity, and safety of leprosy vaccines in humans. Methods In June 2024, three databases were systematically searched with updated search keywords. Randomized controlled trials (RCTs) pertaining to leprosy vaccines for humans which evaluated either therapeutic or prophylactic vaccines in leprosy with a placebo or active comparator arm, with full-text access, were included in the study. There were no restrictions on language, country or date. For the risk of bias assessment in the studies included, the revised Cochrane risk-of-bias 2 tool for RCTs was used. A P value (two-sided) of <0.05 was considered as significant for all tests; however for heterogeneity, a one-sided P value of <0.1 was considered as statistically significant. The quality of generated evidence specific to the desired outcomes were assessed using the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation). The study protocol was registered in PROSPERO (ID: CRD42024561651). Results A total of 2163 studies were retrieved from different databases. After removing duplicates and full text screening, 12 articles were finally selected. Out of these studies, eight used leprosy vaccines on prophylactic basis, while four used leprosy vaccines on therapeutic basis. In therapeutic use of leprosy vaccine, Ramu's score was found to be significantly protective [-3.06 (95% confidence interval (CI): -3.96 to -2.16)] among the recipients of the therapeutic leprosy vaccine. Bacterial index was found to be insignificant [-0.26 (95% CI: -1.54 to 1.03)] among the recipients of therapeutic leprosy vaccine. In subgroup analysis among the eight prophylactic vaccine studies, pooled relative risk was found to be 0.61 (95% CI: 0.41 - 0.91). Interpretation & conclusions The findings of this meta-analysis suggest that both prophylactic and therapeutic leprosy vaccines were significantly better compared to the placebo. Leprosy vaccine in the form of Mw/Mycobacterium welchii/MIP along with combination of World Health Organization (WHO) multi-drug therapy (MDT) or Bacillus Calmette-Guerin (BCG) vaccine along with second line treatment with rifampicin were found to be protective among the recipients.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"293-302"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"50th anniversary of expanded programme on immunization: Shaping the next 50 years in the WHO South-East Asia region.","authors":"Saima Wazed","doi":"10.25259/IJMR_1677_2024","DOIUrl":"10.25259/IJMR_1677_2024","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"259-261"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus vaccination with other health interventions in schools.","authors":"Raj Kumar","doi":"10.25259/IJMR_1295_2024","DOIUrl":"10.25259/IJMR_1295_2024","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"315-318"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate adverse events following immunization (AEFI) in drive-through COVID-19 vaccination campaign in Yogyakarta, Indonesia: A cross-sectional study.","authors":"Lukman Ade Chandra, Hera Nirwati, Dhite Nugroho","doi":"10.25259/IJMR_992_2024","DOIUrl":"10.25259/IJMR_992_2024","url":null,"abstract":"<p><p>Background & objectives The COVID-19 pandemic has led to unprecedented global immunization efforts, with drive-through vaccination campaigns established to expedite and ensure safe coverage. However, research on immediate adverse events following immunization (AEFI) in these settings is limited. This study aims to evaluate the frequency and characteristics of immediate AEFI during drive-through COVID-19 vaccination campaigns in Yogyakarta, Indonesia, using the Sinovac/CoronaVac vaccine Methods This cross-sectional study utilized secondary data from the local vaccine registry managed by the Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Indonesia, from July 27 to September 6, 2021. Participants included individuals aged over 11 yr without underlying medical conditions such as diabetes, hypertension, cancer, or asthma. Key characteristics recorded were age, gender, and AEFI. Results Out of 27,459 registrants, only 20,817 were eligible and received a dose. The median participant age was 20 yr (IQR 10); 47 per cent were male (9,712) and 53 per cent female (11,105). The highest vaccination day was September 6, 2021, with 3,883 doses (18%). Among the 79 participants who experienced AEFI [0.38%; 95% Confidence Interval (CI): 0.30-0.47], the median age was 19 yr (IQR 8); 41 per cent were male (34) and 59 per cent female (48). Systemic adverse events (92%) were more common than local events (6.3%), with dizziness (77.2%) being most prevalent. Interpretation & conclusions The findings of this study suggest that immediate AEFI occurred rarely in the drive-through vaccination setting, indicating that this method appears safe and efficient for COVID-19 vaccinations, particularly in the context of immediate AEFI. Most adverse events were mild, underscoring the importance of preparedness and close monitoring in drive-through vaccination campaign sites to ensure patient safety and enhance vaccine confidence.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"160 3&4","pages":"362-370"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}